Search results for " Coherence"

showing 10 items of 429 documents

Effect of multizone refractive multifocal contact lenses on the Cirrus HD OCT retinal measurements

2011

Background Simultaneous vision multifocal contact lenses are widely used to alleviate the symptoms of presbyopia. These contact lenses create simultaneous retinal images due to the incoming light distribution being divided into two or more focuses. Our aim was to evaluate whether the multizone refractive multifocal contact lenses affect the measurements of the retinal nerve fibre layer (RNFL) and macular thickness using optical coherence tomography (OCT). Methods In this cross-over study, 30 eyes of 30 subjects with a mean age of 50.42 ± 7.82 years were fitted with multizone refractive multifocal contact lenses. Using the RNFL Thickness Analysis mode of the Cirrus HD (Carl Zeiss, Meditec, D…

MaleRetinal Ganglion Cellsmedicine.medical_specialtyMaterials sciencegenetic structuresContact LensesVisual AcuityRefraction Ocularchemistry.chemical_compoundNerve FibersOpticsOptical coherence tomographySignal strengthOphthalmologymedicineHumansÓpticaCross-Over Studiesmedicine.diagnostic_testbusiness.industryRetinalEquipment DesignPresbyopiaPresbyopiaMiddle Agedmedicine.diseaseRefractioneye diseasesContact lensOphthalmologychemistryOftalmologíaFemaleCirrussense organsTomographybusinessTomography Optical CoherenceOptometryClinical and Experimental Optometry
researchProduct

Relationship between Psychophysical Measures of Retinal Ganglion Cell Density and In Vivo Measures of Cone Density in Glaucoma.

2017

Purpose Considerable between-individual variation in retinal ganglion cell (RGC) density exists in healthy individuals, making identification of change from normal to glaucoma difficult. In ascertaining local cone-to-RGC density ratios in healthy individuals, we wished to investigate the usefulness of objective cone density estimates as a surrogate of baseline RGC density in glaucoma patients, and thus a more efficient way of identifying early changes. Design Exploratory cohort study. Participants Twenty glaucoma patients (60% women) with a median age of 54 years and mean deviation (MD) in the visual field of –5 dB and 20 healthy controls (70% women) with a median age of 57 years and a mean…

MaleRetinal Ganglion Cellsmedicine.medical_specialtygenetic structuresGlaucomaCell CountCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInterquartile rangeOphthalmologyOptic Nerve DiseasesmedicinePsychophysicsHumansIntraocular PressureReceiver operating characteristicbusiness.industryRetinalMiddle Agedmedicine.diseaseeye diseasesConfidence intervalHealthy VolunteersPeripheralVisual fieldOphthalmologymedicine.anatomical_structurechemistryRetinal ganglion cell030221 ophthalmology & optometryRetinal Cone Photoreceptor CellsVisual Field TestsREFemalesense organsVisual Fieldsbusiness030217 neurology & neurosurgeryGlaucoma Open-AngleTomography Optical CoherenceOphthalmology
researchProduct

Retrograde Maculopathy in Patients With Glaucoma

2017

PURPOSE Macular optical coherence tomography (OCT) analysis can be used for quantitative measures of optic nerve atrophy at a location far from the optic nerve head. This recently led to the finding of microcystic macular edema (MME), that is vacuolar inclusions in the macular inner nuclear layer, in some glaucoma patients. The involvement of individual retinal layers is yet unclear in glaucoma. In this study we systematically investigated glaucoma-induced changes in macular layers to evaluate whether glaucoma-associated damage extends beyond the macular ganglion cell layer. PATIENTS AND METHODS We included 218 consecutive patients and 282 eyes with confirmed primary open-angle glaucoma or …

MaleRetinal Ganglion Cellsmedicine.medical_specialtygenetic structuresOptic DiskVisual AcuityNerve fiber layerGlaucoma610 Medicine & healthExfoliation SyndromeMacular EdemaRetina03 medical and health sciencesNerve Fibers0302 clinical medicineOphthalmologymedicineHumans610 Medicine & healthMacular edemaGanglion cell layerIntraocular PressureAgedRetrospective StudiesAged 80 and overRetinabusiness.industryMiddle Agedmedicine.diseaseeye diseasesOphthalmologyCross-Sectional Studiesmedicine.anatomical_structureInner nuclear layer030221 ophthalmology & optometryOptic nerveVisual Field TestsMaculopathyFemalesense organsbusinessGlaucoma Open-AngleTomography Optical Coherence030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

How does stress affect life satisfaction during the COVID-19 pandemic? Moderated mediation analysis of sense of coherence and fear of coronavirus

2020

The aim of the present study was to determine the relationship between fear of COVID-19, stress, sense of coherence, and life satisfaction during the coronavirus pandemic. Participants were 907 Polish people (522 women and 385 men). We used the Perceived Stress Scale (PSS-10), Fear of COVID-19 Scale (FOC-6), Sense of Coherence Scale (SOC-29) and the Satisfaction with Life Scale. The relationship between stress and life satisfaction was mediated by the sense of coherence, and the relationship between stress and sense of coherence was moderated by fear of COVID-19. The fear of COVID-19 acted as a buffer in the relationship between stress and sense of coherence weakening the impact of stress o…

MaleSense of CoherencePerceived Stress ScalePersonal SatisfactionAffect (psychology)03 medical and health sciences0302 clinical medicineModerated mediationPandemicStress (linguistics)medicineHumans030212 general & internal medicinePandemicsApplied PsychologyMediation AnalysisSARS-CoV-2Life satisfactionCOVID-19Fear030227 psychiatryPsychiatry and Mental healthClinical PsychologyScale (social sciences)AnxietyFemalemedicine.symptomPsychologySocial psychologyPsychology Health & Medicine
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Colla…

2014

Purpose: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. Methods: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). Results: There were 24 girls and 15 boys with group median age of 13 years (range, 3–17 years). Mean follow-up period was 12.8 months (range, 3–60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabAdolescentVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedOphthalmologyRanibizumabmedicineHumansChildRetrospective StudiesRetinabusiness.industryRetrospective cohort studyGeneral Medicineeye diseasesChoroidal NeovascularizationClinical trialBevacizumabOphthalmologyChoroidal neovascularizationmedicine.anatomical_structureTreatment OutcomeChild PreschoolIntravitreal InjectionsEtiologyFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct